Table 3 The comparison of drug resistance rate of recommended agents for MAC isolates from different studies
From: In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates
NATION/DISTRICT | YEAR | ISOLATE | CLA | RIF | EMB | MXF | RFB | AMI | LZD | STR | SOURCE |
|---|---|---|---|---|---|---|---|---|---|---|---|
THIS STUDY | 2021 | 111 | 5(4.5%) | 92(82.9%) | 60(54.1%) | 67(60.4%) | 24(21.6%) | 3(2.7%) | 80(72.1%) | 19(17.1%) | Â |
GERMANY | 2020 | 98 | 1(1.2%) | - | - | 38(44.7%) | - | 0(0%) | 57(67.1%) | - | [33] |
GERMANY | 2019 | 683 | 17(2.5%) | - | - | 430(63.1%) | - | - | 511(75.0%) | - | [34] |
KOREA | 2018 | 1883 | 95 (5.0%) | 1080 (57.4%) | 1691 (89.8%) | 1054 (56.0%) | - | 166 (8.8%) | 805 (42.8%) | - | [41] |
SWEDEN | 2017 | 229 | 6 (2.6%) | 210 (91.7%) | - | 112 (48.9%) | - | 11 (4.8%) | 118 (51.5%) | - | [39] |
TAIWAN | 2018 | 83 | 0(0%) | - | - | 72(86.7%) | - | 2(2.4%) | 61(73.5%) | 4(4.8%) | [29] |
UK | 2016 | - | 248(19.9%) | 686(55.7%) | 391(31.9%) | - | 58(5.9%) | 100(8.2%) | - | 498(53.0%) | [55] |